BPC-157: what a rat study can establish
A frequently cited tendon experiment is preclinical evidence. It does not by itself establish human benefit or safety.
Identify the actual experiment
Staresinic and colleagues reported a 2003 study of surgically injured Achilles tendons in rats, alongside experiments with cultured tendon cells. The authors reported differences in functional, mechanical and tissue measurements. These were results in the tested experimental models, not a randomized trial of human tendon injuries.
Do not skip the translation step
A positive result in this model cannot determine whether a person benefits, which harms might occur, or how an independently sold material compares with the material studied. This note examines one primary paper; it is not a systematic review of all BPC-157 research.
Safety remains a separate question
FDA identifies potential immunogenicity and peptide-impurity concerns for compounded BPC-157 and says the available safety information is insufficient to determine whether proposed use could harm people. That uncertainty is not evidence of safety. This article provides no dosing or personal-use recommendations.
Follow the sources
- 1Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth Primary animal and cell study, 2003
- 2FDA: Compounding substances that may present significant safety risks FDA safety assessment